- Home
- GNLX vs IMNM Comparison
GNLX vs IMNM Comparison
Compare GNLX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- IMNM
- Stock Information
- Founded
- GNLX 2001
- IMNM 2006
- Country
- GNLX United States
- IMNM United States
- Employees
- GNLX N/A
- IMNM N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- GNLX Health Care
- IMNM Health Care
- Exchange
- GNLX Nasdaq
- IMNM Nasdaq
- Market Cap
- GNLX 103.6M
- IMNM 747.7M
- IPO Year
- GNLX 2023
- IMNM 2020
- Fundamental
- Price
- GNLX $2.27
- IMNM $10.97
- Analyst Decision
- GNLX Strong Buy
- IMNM Strong Buy
- Analyst Count
- GNLX 4
- IMNM 5
- Target Price
- GNLX $18.25
- IMNM $28.60
- AVG Volume (30 Days)
- GNLX 141.5K
- IMNM 874.7K
- Earning Date
- GNLX 11-14-2024
- IMNM 11-13-2024
- Dividend Yield
- GNLX N/A
- IMNM N/A
- EPS Growth
- GNLX N/A
- IMNM N/A
- EPS
- GNLX N/A
- IMNM N/A
- Revenue
- GNLX $8,000.00
- IMNM $10,129,000.00
- Revenue This Year
- GNLX N/A
- IMNM N/A
- Revenue Next Year
- GNLX N/A
- IMNM N/A
- P/E Ratio
- GNLX N/A
- IMNM N/A
- Revenue Growth
- GNLX N/A
- IMNM N/A
- 52 Week Low
- GNLX $1.60
- IMNM $8.33
- 52 Week High
- GNLX $16.60
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- GNLX 38.68
- IMNM 39.61
- Support Level
- GNLX $2.13
- IMNM $10.76
- Resistance Level
- GNLX $2.80
- IMNM $15.13
- Average True Range (ATR)
- GNLX 0.20
- IMNM 0.98
- MACD
- GNLX -0.04
- IMNM -0.29
- Stochastic Oscillator
- GNLX 14.21
- IMNM 4.81
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.